BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38584480)

  • 1. An Immunohistochemical Analysis of Osteopontin and S100 Calcium-binding Protein P is Useful for Subclassifying Large- and Small-duct Type Intrahepatic Cholangiocarcinomas.
    Yoshizawa T; Uehara T; Iwaya M; Nakajima T; Shimizu A; Kubota K; Notake T; Kitagawa N; Masuo H; Sakai H; Hayashi H; Tomida H; Yamazaki S; Hirano S; Ota H; Soejima Y
    Am J Surg Pathol; 2024 Jun; 48(6):751-760. PubMed ID: 38584480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.
    Liau JY; Tsai JH; Yuan RH; Chang CN; Lee HJ; Jeng YM
    Mod Pathol; 2014 Aug; 27(8):1163-73. PubMed ID: 24406866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
    Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
    Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
    Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
    Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns.
    Sigel CS; Drill E; Zhou Y; Basturk O; Askan G; Pak LM; Vakiani E; Wang T; Boerner T; Do RKG; Simpson AL; Jarnagin W; Klimstra DS
    Am J Surg Pathol; 2018 Oct; 42(10):1334-1345. PubMed ID: 30001234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma.
    Xuan Z; Liu L; Zhang G; Zheng X; Jiang J; Wang K; Huang P
    Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130420. PubMed ID: 37433400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma.
    Hamada S; Satoh K; Hirota M; Kanno A; Ishida K; Umino J; Ito H; Kikuta K; Kume K; Masamune A; Katayose Y; Unno M; Shimosegawa T
    Cancer Sci; 2011 Jan; 102(1):150-6. PubMed ID: 21029254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.
    Kinzler MN; Schulze F; Jeroch J; Schmitt C; Ebner S; Gretser S; Bein J; Finkelmeier F; Trojan J; Zeuzem S; Schnitzbauer AA; Demes MC; Reis H; Wild PJ; Walter D
    Histopathology; 2024 May; 84(6):1061-1067. PubMed ID: 38409827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.
    Sarcognato S; Gringeri E; Fassan M; Di Giunta M; Maffeis V; Guzzardo V; Cillo U; Guido M
    Virchows Arch; 2019 Jan; 474(1):29-37. PubMed ID: 30377796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An S100P-positive biliary epithelial field is a preinvasive intraepithelial neoplasm in nodular-sclerosing cholangiocarcinoma.
    Nakanuma Y; Uchida T; Sato Y; Uesaka K
    Hum Pathol; 2017 Feb; 60():46-57. PubMed ID: 27984121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
    Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
    Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
    Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
    Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas.
    Fujikura K; Fukumoto T; Ajiki T; Otani K; Kanzawa M; Akita M; Kido M; Ku Y; Itoh T; Zen Y
    Histopathology; 2016 Dec; 69(6):950-961. PubMed ID: 27410028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
    Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
    Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma.
    Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Srinontong P; Ratasuwan P; Narong K; Nielsen PS; Maekawa Y
    Int J Cancer; 2016 Jan; 138(2):396-408. PubMed ID: 26312563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.
    Tanaka M; Shibahara J; Ishikawa S; Ushiku T; Morikawa T; Shinozaki-Ushiku A; Hayashi A; Misumi K; Tanaka A; Katoh H; Sakuma K; Kokudo T; Inagaki Y; Arita J; Sakamoto Y; Hasegawa K; Fukayama M
    Virchows Arch; 2019 Jan; 474(1):39-46. PubMed ID: 30349952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
    Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
    Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.